Výsledky vyhledávání - Cornelia Quadt
- Zobrazuji výsledky 1 - 16 z 16
-
1
Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors Autor Yuichi Ando, Satoru Iwasa, Shunji Takahashi, Hideo Saka, Tomoyuki Kakizume, Kazuto Natsume, Naoko Suenaga, Cornelia Quadt, Yasuhide Yamada
Vydáno 2018Artigo -
2
Phase I dose‐escalation study of buparlisib (<scp>BKM</scp>120), an oral pan‐class I <scp>PI</scp>3K inhibitor, in Japanese patients with advanced solid tumors Autor Yukio Ando, Megumi Inada‐Inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi
Vydáno 2014Artigo -
3
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design Autor Cristian Massacesi, Emmanuelle di Tomaso, Patrick Urban, Caroline Germa, Cornelia Quadt, Lucia Trandafir, Paola Aimone, Nathalie Fretault, Bharani Dharan, Ranjana Tavorath, Samit Hirawat
Vydáno 2016Revisão -
4
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models Autor Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski, Andrew J. Massey, Chantale T. Guy, Josef Brueggen, Cornelia Quadt, Alan Buckler, Robert Cozens, Martin J. Drysdale, Carlos Garcı́a-Echeverrı́a, Patrick Chêne
Vydáno 2008Artigo -
5
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer Autor Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita J. Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O’Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn
Vydáno 2013Artigo -
6
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Autor Bernd Schlereth, Cornelia Quadt, Torsten Dreier, Peter Kufer, Grit Lorenczewski, Nadja Prang, Christian Brandl, Sandra Lippold, KATHY E. COBB, Kathleen M. Brasky, Eugen Leo, Ralf C. Bargou, Krishna K. Murthy, Patrick A. Baeuerle
Vydáno 2005Artigo -
7
The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth Autor Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avşar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett, Dennis J. Slamon
Vydáno 2013Artigo -
8
First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors Autor Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn D. Britten, Karen S. Jacks, Monica Mita, Vali Papadimitrakopoulou, Tim Pluard, Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, Cristina Fernandez‐Ibarra, Hong Lü, Stuart Bailey, Sandra Chica, Udai Banerji
Vydáno 2013Artigo -
9
Alpelisib Plus Fulvestrant in <i>PIK3CA</i>-Altered and <i>PIK3CA</i>-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer Autor Dejan Juric, Filip Janků, Jordi Rodón, Howard A. Burris, Ingrid A. Mayer, Martin Schüler, Ruth Seggewiß-Bernhardt, Marta Gil-Martín, Mark R. Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S. Rugo
Vydáno 2018Artigo -
10
89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft Autor Thijs H. Oude Munnink, Maarten A. de Korte, Wouter B. Nagengast, Hetty Timmer‐Bosscha, Carolina P. Schröder, Johan R. de Jong, Guus A.M.S. van Dongen, Michael Rugaard Jensen, Cornelia Quadt, Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries
Vydáno 2009Artigo -
11
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study Autor Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Janků, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiß-Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga
Vydáno 2018Artigo -
12
<sup>89</sup>Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922 Autor Wouter B. Nagengast, Maarten A. de Korte, Thijs H. Oude Munnink, Hetty Timmer‐Bosscha, Wilfred F.A. den Dunnen, Harry Hollema, Johan R. de Jong, Michael Rugaard Jensen, Cornelia Quadt, Carlos Garcı́a-Echeverrı́a, Guus A.M.S. van Dongen, Marjolijn N. Lub–de Hooge, Carolien P. Schröder, Elisabeth G.E. de Vries
Vydáno 2010Artigo -
13
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer Autor Moshe Elkabets, Sadhna Vora, Dejan Juric, Natasha Morse, Mari Mino‐Kenudson, Taru Muranen, Jessica J. Tao, Ana Bosch Campos, Jordi Rodón, Yasir H. Ibrahim, Violeta Serra, Vanessa Rodrik-Outmezguine, Saswati Hazra, Sharat Singh, Philip Kim, Cornelia Quadt, Manway Liu, Alan Huang, Neal Rosen, Jeffrey A. Engelman, Maurizio Scaltriti, José Baselga
Vydáno 2013Artigo -
14
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer Autor Jordi Rodón, José Alejandro Pérez Fidalgo, Ian E. Krop, Howard A. Burris, Ángel Guerrero‐Zotano, Carolyn D. Britten, Carlos Becerra, Jan H.M. Schellens, Donald Richards, Martin Schüler, Maysa Abu‐Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, José Baselga
Vydáno 2018Artigo -
15
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor Autor Dejan Juric, Pau Castel, Malachi Griffith, Obi L. Griffith, Helen Won, Haley Ellis, Saya H. Ebbesen, Benjamin J. Ainscough, Avinash Ramu, Gopa Iyer, Ronak Shah, Tiffany G. Huynh, Mari Mino‐Kenudson, Dennis C. Sgroi, Steven J. Isakoff, Ashraf Thabet, Leila Elamine, David B. Solit, Scott W. Lowe, Cornelia Quadt, Malte Peters, Adnan Derti, Robert Schegel, Alan Huang, Elaine R. Mardis, Michael F. Berger, José Baselga, Maurizio Scaltriti
Vydáno 2014Artigo -
16
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers Autor Stéphane Ferretti, Jacques Hamon, Ruben de Kanter, Clemens Scheufler, Rita Andraos-Rey, Stéphanie Barbé, Elisabeth Bechter, Jutta Blank, Vincent Bordas, Ernesta Dammassa, Eric A. Decker, Noemi Di Nanni, Marion Dourdoigne, Elena Gavioli, Marc Hattenberger, Alisa Heuser, Christelle Hemmerlin, Jürgen Hinrichs, Gráinne Kerr, Laurent Laborde, Isabel Jaco, Eloísa Jiménez Núñez, Hans‐Joerg Martus, Cornelia Quadt, Markus Reschke, Vincent Romanet, Fanny Schaeffer, Joseph Schoepfer, Maxime Schrapp, Ross Strang, Hans Voshol, Markus Wartmann, Sarah Welly, Frédéric J. Zécri, Francesco Hofmann, Henrik Möbitz, Marta Cortés-Cros
Vydáno 2024Artigo
Vyhledávací nástroje:
Související témata
Medicine
Internal medicine
Cancer
Cancer research
Oncology
Breast cancer
Biochemistry
Biology
Gene
Adverse effect
Chemistry
Pharmacology
Gastroenterology
Tolerability
Heat shock protein
Hsp90
Hsp90 inhibitor
Molecular biology
Pharmacokinetics
Biotechnology
Chemotherapy
Genetics
In vivo
PI3K/AKT/mTOR pathway
Pharmacodynamics
Phases of clinical research
Rash
Response Evaluation Criteria in Solid Tumors
Trastuzumab
Apoptosis